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OBJECTIVES The objective of this study was to analyze the influence of coronary artery revascularization
in patients with ventricular arrhythmias.
BACKGROUND Coronary artery revascularization is an effective treatment for myocardial ischemia; however,
its effect on ventricular arrhythmias not related to an acute ischemic event has not been
carefully studied.
METHODS Sixty-four patients (58 men, mean age 65 6 8 years old) with prior myocardial infarction,
spontaneous ventricular arrhythmias not related to an acute ischemic event (55 ventricular
tachycardia, 9 ventricular fibrillation) and coronary lesions requiring revascularization were
studied prospectively. Electrophysiological study was performed before and after revascular-
ization, and events during follow-up were analyzed.
RESULTS At initial study 61 patients were inducible into sustained ventricular arrhythmias. After
revascularization, in 62 survivors, 52 out of 59 patients previously inducible were still
inducible (group A), and 10 patients were noninducible (group B). No differences were found
in clinical, hemodynamic, therapeutic and electrophysiological characteristics between both
groups. During 32 6 26 months follow-up, 28/52 patients in group A (54%) and 4/10
patients in group B (40%) had arrhythmic events (p 5 0.46). An ejection fraction ,30%
predicted recurrent arrhythmic events (p 5 0.02), but not the presence of demonstrable
ischemia before revascularization (p 5 0.42), amiodarone (p 5 0.69) or beta-adrenergic
blocking agent therapy (p 5 0.53). Total mortality was 10% in both groups.
CONCLUSIONS In patients with ventricular arrhythmias in the chronic phase of myocardial infarction,
probability of recurrence is high despite coronary artery revascularization, but mortality is low
if combined with appropriate antiarrhythmic therapy. Recurrences are related to the presence
of a low ejection fraction but not to demonstrable ischemia before revascularization,
amiodarone or beta-blocker therapy nor are they the results of electrophysiological testing
after revascularization. (J Am Coll Cardiol 2001;37:529–33) © 2001 by the American
College of Cardiology
The investigation of patients with sustained ventricular
arrhythmias in the chronic phase of a myocardial infarction
(MI) usually includes the study of coronary artery anatomy
in order to detect those that might benefit from coronary
artery revascularization. If indicated, coronary artery revas-
cularization has proven to be an effective therapy for
myocardial ischemia (1,2). However, limited information is
available concerning the role of coronary artery revascular-
ization in the modification of the electrophysiologic
substrate and in the prevention of recurrences of ventric-
ular arrhythmias in this group of patients (3–9). In this
study, the effects of coronary artery revascularization on
inducibility of ventricular arrhythmias and its influence
on arrhythmia recurrence during follow-up were prospec-
tively analyzed.
The role of ischemia in the occurrence of ventricular
arrhythmias was also analyzed by comparing outcome after
successful revascularization in patients with and without
demonstrable myocardial ischemia before revascularization.
METHODS
Patients. We conducted a prospective study in 64 consec-
utive patients presenting to our institution between Febru-
ary 1994 and December 1999 with sustained ventricular
arrhythmias in the chronic phase of an MI and in whom
coronary artery revascularization was indicated after clinical
and angiographic evaluation. Patients, in whom clinical,
electrocardiographic or enzymatic data suggested an acute
ischemic event as a trigger of the arrhythmia, were excluded.
Coronary artery anatomy. Coronary artery angiography
was performed using standard techniques between one and
eight days after the arrhythmic event.
Indication for coronary artery revascularization. Indica-
tion for revascularization was established either by the
presence of significant coronary artery lesions and the
suspicion of myocardial ischemia from clinical, electrocar-
diographic, stress testing or scintigraphic data or by the
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severity of the lesions at the coronary angiogram (three-
vessel disease or two-vessel disease including a proximal
lesion in the left anterior descending coronary artery) but
without evidence of myocardial ischemia.
Coronary artery revascularization. Coronary artery revas-
cularization was performed between 3 and 10 days after
coronary angiography. In patients with single- or uncom-
plicated double-vessel disease, percutaneous transluminal
coronary angioplasty was performed. In patients with com-
plicated double-vessel disease or triple-vessel disease, coro-
nary artery bypass graft, using saphenous grafts and, when-
ever possible, internal mammary arteries, was performed.
Electrophysiological testing. Electrophysiological testing
was simultaneously performed with the coronary angiogra-
phy between one and eight days after the arrhythmic event,
after informed written consent, in the fasting state and using
mild sedation. All antiarrhythmic drugs were eliminated 5
half-life times before the procedure, except for amiodarone
and beta-adrenergic blocking agents that were used at the
same dose as before the study. Electrophysiological testing
was performed using two cuadripolar 6F catheters for
recording and stimulation. The protocol for ventricular
programmed stimulation used one to three premature beats
during sinus rhythm and at three driven cycle lengths (600,
500 and 430 ms) at the right ventricular apex. The patient
was considered inducible if a sustained ventricular tachycar-
dia (.30 s) or a hemodynamically unstable arrhythmia
requiring cardioversion was initiated. The patient was con-
sidered noninducible if no sustained arrhythmia was in-
duced upon completion of the protocol.
Second electrophysiological testing. A second electro-
physiological study was performed between 3 and 15 days after
coronary artery revascularization using the same protocol as the
previous one. No new antiarrhythmic drugs were used between
the first and the second study, and those patients on amioda-
rone or beta-blockers continued at the same dose regimen.
Antiarrhythmic treatment. The antiarrhythmic treatment
was decided after completion of the second electrophysio-
logical study, mainly on the basis of the clinical arrhythmia
and the results of the programmed ventricular stimulation.
Follow-up. Patients were followed at three-month inter-
vals in the outpatient clinic. A patient was considered to be
suffering from a recurrent arrhythmic event if a sustained
ventricular arrhythmia was documented either on a 12-lead
electrocardiogram or on a defibrillator electrogram or if sudden
death occurred. A patient was considered to be suffering from
recurrent myocardial ischemia if anginal complaints recurred
after revascularization, in which case a noninvasive evaluation
using a stress test and a second coronary angiography was
performed to evaluate the results of revascularization.
Statistical analysis. Statistical calculations were performed
using the SPSS package. The Fisher exact test or the chi-
square test was used for categorical variables. One-way analysis
of variance or the Student t test was used for comparison of
continuous variables. Survival curves were plotted using the
Kaplan-Meier method and analyzed by the log-rank test. A
value of p , 0.05 was considered statistically significant.
RESULTS
Fifty-eight out of the 64 patients were men, and mean age
was 65 6 8 years old (range 38 to 77 years old). Previous MI
was anterior in 60%, inferior in 30% and both in 10% of
patients. Mean ejection fraction was 38 6 9% (range 20% to
65%). None of the patients had had coronary artery revas-
cularization before the clinical arrhythmic event. The spon-
taneous arrhythmic event was sustained monomorphic ven-
tricular tachycardia in 55 patients and ventricular fibrillation
in 9 patients (Fig. 1). The spontaneous arrhythmic event
occurred between 1 and 95 months (mean 11 6 35 months)
Abbreviations and Acronyms
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
Figure 1. Flow-chart relating clinical arrhythmia, results of pre- and post-revascularization electrophysiological studies (1st EPS and 2nd EPS) and
follow-up (F-up). Death 5 death during surgery; NA 5 no arrhythmia recurrence during follow-up; NI 5 noninducible; SCD 5 sudden cardiac death
during follow-up; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia. Numbers indicate patients in each category.
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after the MI. At the moment of the clinical event, three
patients were on amiodarone, and 21 were on beta-blocker
therapy.
Eight patients had single-vessel disease (.70% narrow-
ing of the artery); 12 patients had double-vessel disease, and
44 patients had triple-vessel disease. In 45 patients revas-
cularization was indicated by angiographic and clinical data;
in 19 patients the indication was established solely on the
basis of coronary anatomy.
Percutaneous transluminal coronary angioplasty was suc-
cessfully performed in 16 patients, and multiple coronary
artery bypass graft was performed in 48 patients. Two of the
patients with triple-vessel disease and evidence of ischemia
died during surgery.
Initial electrophysiological study. An electrophysiological
study was performed in all 64 patients. At the time of the
study, 10 patients were receiving amiodarone (seven since
the spontaneous arrhythmic event and three chronically
because of other arrhythmias), and 21 were receiving beta-
blockers. In 61 patients, programmed electrical stimulation
induced a sustained ventricular arrhythmia. In 53 patients
the induced arrhythmia was a monomorphic ventricular
tachycardia (mean cycle length 270 6 30 ms), and in eight
patients ventricular fibrillation was the arrhythmia induced.
In three patients no sustained ventricular arrhythmia could
be induced (Fig. 1). No differences were observed in
inducibility among patients with ventricular tachycardia or
ventricular fibrillation as clinical arrhythmia and with or
without amiodarone or beta-blocker treatment.
Electrophysiological study after coronary artery revascu-
larization. In 52 patients, programmed electrical stimula-
tion induced a sustained ventricular arrhythmia (group A).
In 46 patients the induced arrhythmia was monomorphic
ventricular tachycardia (mean cycle length 282 6 50 ms)
and in six patients a ventricular fibrillation. In 10 patients
(eight with ventricular tachycardia and two with ventricular
fibrillation as clinical arrhythmia) no sustained arrhythmia
could be induced (group B). Comparing both studies, 5 out
of the 53 patients with ventricular tachycardia at the initial
study became noninducible, and in one patient ventricular
fibrillation was now the arrhythmia induced. Two of the
eight patients with ventricular fibrillation became noninduc-
ible, and in one patient ventricular tachycardia was now the
arrhythmia induced, whereas the three noninducible pa-
tients in the first study remained noninducible in the second
study (Fig. 1). No differences were observed among patients
with inducible or noninducible arrhythmias concerning
clinical data, number of vessels affected, indication for revas-
cularization, ejection fraction, type of revascularization and
presence of amiodarone or beta-blocker therapy (Table 1).
In 36 patients an automatic defibrillator was implanted (4
abdominal and 32 pectoral), and 14 of them had amioda-
rone as adjunctive therapy. The remaining 26 patients were
treated with antiarrhythmic drugs (18 with amiodarone and
8 with sotalol). Twenty-one patients were on beta-blocker
therapy before the revascularization procedure and remained
on that therapy.
Follow-up. Mean follow-up time was 32 6 26 months
(31 6 26 for group A and 35 6 29 for group B). During
follow-up, 28 patients in group A (54%) and 4 patients in
group B (40%) had recurrent arrhythmic events (log rank 5
0.5, p 5 0.46) (Fig. 1 and 2). All recurrent arrhythmic
events were ventricular tachycardia, except for one patient in
Figure 2. Kaplan-Meier analysis of freedom from recurrent arrhythmic
events during follow-up according to the inducibility of ventricular ar-
rhythmias after coronary artery revascularization. The difference between
the groups was not significant (p 5 0.46) by the log-rank test. Ind 5 the
patient was inducible; NInd 5 the patient was not inducible.
Table 1. Clinical, Hemodynamic, Therapeutic and Follow-Up
Data According to Inducibility of Ventricular Arrhythmias After
Coronary Artery Revascularization
Inducible
After
Revascularization
Noninducible
After
Revascularization
p
Value
n 52 10
Follow-up (months) 31 6 26 35 6 29
Ejection fraction (%) 37 6 9 39 6 8 0.55
Ejection fraction , 30 12 1 0.35
Ejection fraction $ 30 40 9
Bypass surgery 39 7 0.74
Coronary angioplasty 13 3
Ischemia demonstrated 35 8 0.43
No ischemia demonstrated 17 2
Amiodarone treatment 9 1 0.13
No amiodarone treatment 43 9
Beta-blocker treatment 18 3 0.44
No beta-blocker treatment 34 7
One-vessel disease 6 2 0.61
Two-vessel disease 11 1
Three-vessel disease 35 7
Clinical arrhythmia: VT 46 9 0.89
Clinical arrhythmia: VF 6 1
Recurrent arrhythmic event 28 (54%) 4 (40%) 0.46
Total death 5 (10%) 1 (10%) 0.98
VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
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group A on amiodarone therapy that suffered sudden death.
In patients with an automatic defibrillator implanted, suc-
cessful radiofrequency ablation was performed in six pa-
tients due to recurrent slow ventricular tachycardia during
follow-up, and five received amiodarone due to recurrent
ventricular tachycardia not amenable to radiofrequency ab-
lation. In the three survivors with recurrent arrhythmic
events in group B, an automatic defibrillator was implanted.
Five patients died in group A (one sudden death, one
fatal stroke and one pulmonary, one tracheal and one
cerebral malignancy). One patient died of cardiac insuffi-
ciency in group B. Total mortality was 10% in both groups.
One single patient in group A that underwent percuta-
neous transluminal coronary angioplasty of a single lesion
and had no arrhythmic recurrences during follow-up pre-
sented with recurrent myocardial ischemia demonstrated by
a positive stress test. Coronary angiography demonstrated
restenosis of the left anterior descending coronary artery,
and a second successful angioplasty and stent placement was
performed.
Incidence of events according to the presence of myocar-
dial ischemia before the revascularization procedure.
During follow-up, 21 of 43 patients (49%) with evidence of
ischemia before revascularization had arrhythmic events,
compared with 11 of 19 patients (58%) with no evidence of
ischemia before revascularization (log rank 5 0.66, p 5
0.42) (Table 2).
Incidence of events according to the left ventricular
ejection fraction (LVEF). In 9 of 13 patients (69%) with
an LVEF ,30%, arrhythmic events occurred during follow-
up, compared with 23 of 49 patients (47%) with an LVEF
$30% (log rank 5 4.9, p 5 0.02) (Table 2; Fig. 3).
Incidence of events according to the presence of amio-
darone as antiarrhythmic therapy. Fourteen of 30 patients
(47%) without amiodarone therapy had arrhythmic events,
compared with 18 of 32 patients (57%) on amiodarone
therapy (log rank 5 0.16, p 5 0.69) (Table 2).
DISCUSSION
The influence of acute ischemic events in the genesis of
sustained ventricular arrhythmias is one of the more con-
troversial issues concerning patients in the chronic phase of
an MI. The discussion is not only theoretical, but it has
important practical aspects. If an acute ischemic event is
responsible for the arrhythmia, prevention of ischemia
should also prevent the occurrence of the arrhythmia. This
has been clearly demonstrated in a highly selected group of
patients with documented ischemia-related arrhythmias
(mainly polymorphic ventricular tachycardia or ventricular
fibrillation) in whom surgical revascularization alone effec-
tively controlled the arrhythmias (7,8). However, in the
majority of patients with an old MI, an ischemia-related
mechanism as trigger for the arrhythmias cannot be dem-
onstrated although neither can it be excluded. Correction of
coronary artery lesions susceptible to revascularization, es-
pecially if some objective proof of reversible ischemia is
present, should prevent arrhythmia occurrence if ischemia
behaved as a trigger for the arrhythmia.
In this study, the influence of ischemia on the occurrence
of ventricular arrhythmias was analyzed using two parame-
ters: inducibility of arrhythmias before and after coronary
Figure 3. Kaplan-Meier analysis of freedom from recurrent arrhythmic
events during follow-up according to the left ventricular ejection fraction
(EF) before surgery. The difference between the groups was significant
(p 5 0.02) by the log-rank test. EF , 30% 5 the patient had an ejection
fraction , 30%; EF $ 30% 5 the patient had an ejection fraction $30%.
Table 2. Clinical, Hemodynamic, Therapeutic and Follow-Up
Data According to the Presence of Recurrent Arrhythmic
Events During Follow-up
Recurrent
Arrhythmic
Event
No Recurrent
Arrhythmic
Event
p
Value
n 32 30
Follow-up (months) 33 6 24 34 6 27
Ejection fraction (%) 37 6 9 38 6 9 0.64
Ejection fraction , 30 9 4 0.02
Ejection fraction $ 30 23 26
Bypass surgery 25 21 0.87
Coronary angioplasty 7 9
Ischemia demonstrated 21 22 0.42
No ischemia demonstrated 11 8
Amiodarone treatment 18 14 0.69
No amiodarone treatment 14 16
Beta-blocker treatment 10 11 0.61
No beta-blocker treatment 22 19
One-vessel disease 5 3 0.81
Two-vessel disease 6 6
Three-vessel disease 21 21
Inducible after revascularization 28 24 0.46
Noninducible after revascularization 4 6
Clinical arrhythmia: VT 29 26 0.76
Clinical arrhythmia: VF 3 4
VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
532 Brugada et al. JACC Vol. 37, No. 2, 2001
Revascularization and Ventricular Arrhythmias February 2001:529–33
artery revascularization and arrhythmia recurrence during
follow-up. Patients were divided into those with and those
without reversible ischemia demonstrated before revascular-
ization and those with and without inducible arrhythmias
after revascularization.
Do coronary artery revascularizations modify the electro-
physiological substrate? Our results clearly show that,
despite effective coronary artery revascularization, the ar-
rhythmia substrate is not modified in a significant propor-
tion of patients. This is demonstrated by the high degree of
inducibility after revascularization (only 9 of 61 patients
became noninducible) but also by the high recurrence rate of
ventricular arrhythmias during follow-up (32 of 61 pa-
tients). These results are similar to the ones of Geelen et al.
(3) in a group of 18 patients with similar characteristics who
presented with a 67% incidence of inducibility and a 66%
incidence of appropriate shocks after revascularization and
defibrillator implantation. Manolis et al. (5) found, how-
ever, in a similar group of 56 patients, that 33% of patients
with inducible sustained arrhythmias became noninducible
after revascularization, and only 30% of patients had major
arrhythmic events during follow-up. Similar studies per-
formed in survivors of cardiac arrest have shown that 47% of
patients became noninducible after revascularization (espe-
cially those with ventricular fibrillation as induced arrhyth-
mia). The incidence of arrhythmic events during follow-up
was 10%, suggesting that ischemia did play a role in the
occurrence of cardiac arrest in these patients (4). Ecker et al.
(9) presented a clinical case some years ago that suggested
that coronary artery revascularization could be an effective
method of treatment in intractable ventricular tachycardia.
A selected group of patients with coronary artery disease
and ventricular arrhythmias induced during exercise was
studied by Berntsen et al. (7). After revascularization,
ventricular arrhythmias were abolished in all patients with
ventricular fibrillation as clinical arrhythmia and in 90% of
patients with ventricular tachycardia. In this group of
patients with exercise-induced arrhythmias, ischemia should
definitively play a role in such an occurrence, and revascu-
larization seems the treatment of choice. In our series, the
proportion of patients with still inducible arrhythmias or
with arrhythmia recurrence is similar among those with and
without demonstrable ischemia before revascularization.
This suggests that the presence of demonstrable reversible
ischemia is not a marker for an ischemia-related mechanism
for arrhythmias and that demonstration of reversible isch-
emia represents a different subset of patients from those
with exercise-induced arrhythmias in whom ischemia acts as
the trigger for the arrhythmia.
How to approach a patient with an old MI, sustained
ventricular arrhythmias and coronary artery lesions re-
quiring revascularization. In all published series, survival
after coronary artery revascularization in patients with ven-
tricular arrhythmias is excellent (3–8). Cardiac mortality is
low and between 5% and 10% at two to five years follow-up.
In our own series, total mortality is 10%, and cardiac
mortality is less than 3% at three-year follow-up. This
suggests that the combination of coronary artery revascular-
ization and antiarrhythmic therapy (drug therapy or defi-
brillator implantation) is an excellent combination and
should be used systematically.
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